See more : Blueberries Medical Corp. (BBM.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Enfusion, Inc. (ENFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enfusion, Inc., a leading company in the Software – Application industry within the Technology sector.
- Fathom Nickel Inc. (FNI.CN) Income Statement Analysis – Financial Results
- Samyang Corporation (145990.KS) Income Statement Analysis – Financial Results
- Ivy Cosmetics Corporation (4918.T) Income Statement Analysis – Financial Results
- alstria office REIT-AG (AOX.SW) Income Statement Analysis – Financial Results
- United Orthopedic Corporation (4129.TWO) Income Statement Analysis – Financial Results
Enfusion, Inc. (ENFN)
About Enfusion, Inc.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 174.54M | 150.35M | 111.70M | 79.57M | 59.03M |
| Cost of Revenue | 57.64M | 47.10M | 31.85M | 21.36M | 16.96M |
| Gross Profit | 116.89M | 103.25M | 79.86M | 58.21M | 42.07M |
| Gross Profit Ratio | 66.97% | 68.67% | 71.49% | 73.16% | 71.27% |
| Research & Development | 19.89M | 17.16M | 153.40M | 6.32M | 4.15M |
| General & Administrative | 64.64M | 68.76M | 150.61M | 35.89M | 16.63M |
| Selling & Marketing | 20.42M | 29.29M | 51.73M | 9.93M | 7.43M |
| SG&A | 85.05M | 98.05M | 202.34M | 45.82M | 24.05M |
| Other Expenses | 0.00 | -638.00K | -1.19M | 82.00K | -3.00K |
| Operating Expenses | 104.95M | 115.21M | 355.74M | 52.13M | 28.20M |
| Cost & Expenses | 162.59M | 162.31M | 387.58M | 73.49M | 45.16M |
| Interest Income | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Interest Expense | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Depreciation & Amortization | 9.99M | 6.60M | 3.98M | 2.29M | 1.16M |
| EBITDA | 21.94M | -5.62M | -271.91M | 8.37M | 15.02M |
| EBITDA Ratio | 12.57% | -3.74% | -244.49% | 10.62% | 25.45% |
| Operating Income | 11.95M | -11.96M | -275.88M | 6.07M | 13.87M |
| Operating Income Ratio | 6.85% | -7.96% | -246.99% | 7.63% | 23.50% |
| Total Other Income/Expenses | -464.00K | -225.00K | -5.78M | -1.58M | -727.00K |
| Income Before Tax | 11.48M | -12.19M | -281.66M | 4.49M | 13.14M |
| Income Before Tax Ratio | 6.58% | -8.11% | -252.16% | 5.65% | 22.26% |
| Income Tax Expense | 2.23M | 1.07M | 579.00K | 433.00K | 486.00K |
| Net Income | 6.03M | -13.26M | -282.24M | 4.06M | 12.66M |
| Net Income Ratio | 3.45% | -8.82% | -252.68% | 5.10% | 21.44% |
| EPS | 0.10 | -0.16 | -4.30 | 0.04 | 0.11 |
| EPS Diluted | 0.07 | -0.16 | -4.30 | 0.04 | 0.11 |
| Weighted Avg Shares Out | 88.20M | 85.39M | 65.58M | 113.05M | 113.05M |
| Weighted Avg Shares Out (Dil) | 129.43M | 85.39M | 65.58M | 113.05M | 113.05M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Enfusion, Inc. (ENFN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm Today!
An Investigation Has Commenced on Behalf of Enfusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ENFN Losses.
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Stockholders to Contact the Firm!
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Enfusion: Growth Should Accelerate In Coming Quarters
Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Enfusion, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Enfusion (ENFN)
Source: https://incomestatements.info
Category: Stock Reports